AdaMunix
AdaMunix
  • Sign In
  • Create Account

  • Bookings
  • My Account
  • Signed in as:

  • filler@godaddy.com


  • Bookings
  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

    Account


    • Bookings
    • My Account
    • Sign out


    • Sign In
    • Bookings
    • My Account

    Disruptive Platform Eliminating Anti-drug Antibodies

    Disruptive Platform Eliminating Anti-drug Antibodies Disruptive Platform Eliminating Anti-drug Antibodies Disruptive Platform Eliminating Anti-drug Antibodies

    A New Era in Drug Development

    Learn More

    Mission and Vision

    Vision

      Improve drug development and patient lives by eliminating anti-drug antibodies (ADAs) known to reduce drug efficacy and lead to adverse events

    Mission

      Become the premier drug development partner of choice with the first and only targeted solution that eliminates ADA

    Leading the paradigm-breaking development of ADA-stealth protein therapeutics

    Company Highlights

      

    Led by serial entrepreneurs with deep scientific expertise and a successful track record of biotech start-ups.

      

    The world's first and only targeted solution for anti-drug antibodies (ADAs), a major un-breakable barrier to antibody, enzyme and gene therapies

      

    OncoC4 spinoff leveraging scientific, manufacturing and clinical expertise of OncoC4

    Co-Founders

    LinkedIn
    LinkedIn

    Leadership with a Track Record of Execution & Success

    About AdaMunix Platform

    Click the "Next" button below to view more

    For further information

    Pan Pan, PhD, MBA

    Senior Vice President

    Head of Business Development

    718-902-6624

    ppan@oncoc4.com

    Ryan Cui, PhD, MBA

    Executive Director

    Investor Relationship

    zcui@acroimmune.cn

    Greater China

    Copyright © 2025 AdaMunix, Inc. - All Rights Reserved.

    We value your privacy

    We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept", you consent to our use of cookies.

    DeclineAccept